By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


The Medicines Company 

8 Sylvan Way

Parsippany  New Jersey  07054  U.S.A.
Phone: 973-290-6000 Fax: 973-656-9898


The Medicines Company's purpose is to save lives, alleviate suffering and contribute to the economics of healthcare by focusing on 3,000 leading acute/intensive care hospitals worldwide. Its vision is to be a leading provider of solutions in three areas: acute cardiovascular care, surgery and perioperative care, and serious infectious disease care. The company operates in the Americas, Europe and the Middle East, and Asia Pacific regions with global centers today in Parsippany, NJ, USA and Zurich, Switzerland.

Key Statistics

Ownership: Public

Web Site: The Medicines Company
Employees: 500+
Symbol: MDCO


UCB, Inc.  Contract manufacturing of Bivalirudin peptide active ingredient


Company News
The Medicines Company (MDCO) And SymBio Pharmaceuticals Establish Strategic Partnership For IONSYS (Fentanyl Iontophoretic Transdermal System) In Japan 10/7/2015 12:04:24 PM
The Medicines Company (MDCO) Announces BARDA Exercises Next Option On Contract For Support Of The Development Of CARBAVANCE (Meropenem/RPX7009) For Drug-Resistant Gram-Negative Pathogens 10/1/2015 12:48:07 PM
The Medicines Company (MDCO) Announces Participation At IDWeek 2015 Meeting 10/1/2015 9:14:39 AM
The The Medicines Company (MDCO) Receives CHMP Positive Opinion For IONSYS To Treat Post-Operative Pain In Adult Patients 9/25/2015 8:45:21 AM
New Treatment Options For Carbapenem-Resistant Enterobacteriaceae (CRE) Infection Needed, According To Study By The Medicines Company (MDCO) 9/21/2015 12:48:46 PM
The Medicines Company (MDCO) Reports Discovery Of New Series Of Beta-Lactamase Inhibitors At ICAAC/ICC 2015 9/21/2015 11:45:01 AM
The Medicines Company (MDCO) Announces Participation At ICAAC/ICC 2015 Meeting 9/15/2015 3:28:11 PM
The Medicines Company (MDCO) Release: MATRIX Trial Results Presented At Hot Line Session Of ESC Congress 2015 And Simultaneously Published In The New England Journal of Medicine 9/2/2015 11:07:09 AM
The Medicines Company (MDCO) Release: Analysis From CHAMPION PHOENIX Trial Highlight The Efficacy Of Cangrelor Among Patients Undergoing PCI Via The Radial Approach 9/1/2015 10:21:52 AM
The Medicines Company (MDCO) Appoints Dr. Fred Eshelman As Non-Executive Chairman Of The Board 8/31/2015 8:44:47 AM